Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...

Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...

Eli Lilly & Co. shares gained as its main rival in weight-loss drugs posted disappointing results from a clinical trial.

( MENAFN - Baystreet) Merck (NYSE:MRK) on Wednesday said it has snagged the rights to an experimental weight loss pill from ...

A British mum-of-two died suddenly at the age of 34 recently after allegedly falling violently ill following the consumption ...

after its shares had struggled to keep pace with Eli Lilly and it suffered a setback from disappointing results for an ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Interestingly, a large proportion of the weight loss product ... 1 oral pill), and Retatrutide (Glucagon/GIP/GLP-1 triple receptor agonist subcutaneous injection). Retatrutide, Lilly's triple ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...